Search

Author/Creator Robson, M E

1. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. (23rd January 2019)

Authors:
Robson, M E; Tung, N; Conte, P; Im, S -A; Senkus, E; Xu, B; Masuda, N; Delaloge, S; Li, W; Armstrong, A; Wu, W; Goessl, C; Runswick, S; Domchek, S M
Journal:
Annals of oncology
Issue:
Volume 30:Number 4(2019)
Page Start:
558
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. Issue 1 (4th October 2010)

Authors:
Schrader, K A; Masciari, S; Boyd, N; Salamanca, C; Senz, J; Saunders, D N; Yorida, E; Maines-Bandiera, S; Kaurah, P; Tung, N; Robson, M E; Ryan, P D; Olopade, O I; Domchek, S M; Ford, J; Isaacs, C; Brown, P; Balmana, J; Razzak, A R; Miron, P
Journal:
Journal of medical genetics
Issue:
Volume 48:Issue 1(2011)
Page Start:
64
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗